Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 24053368.
- Also identified by DOI 10.1111/bju.12396.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether sequence variants within the FGF23 gene are associated with the risk of developing prostate cancer in a Korean population. Five common single nucleotide polymorphisms (SNPs) in the FGF23 gene were assessed in 272 patients with prostate cancer and 173 control subjects with benign prostatic hyperplasia. Single-locus analyses were conducted using conditional logistic regression. In addition, we performed a haplotype analysis for the five FGF23 SNPs tested. Three SNPs in the FGF23 gene (rs11063118, rs13312789 and rs7955866) were associated with an increased risk of prostate cancer in our study population. Odds ratios for homozygous variants vs wild-type variants ranged from 1.68 (95% confidence interval [CI]: 1.15-2.46) to 1.79 (95% CI: 1.16-2.75). This is the first study showing that genetic variations in FGF23 increase prostate cancer susceptibility.
Medical subject headings
- Asian People
- Fibroblast Growth Factors
- Polymorphism, Single Nucleotide
- Prostatic Neoplasms